FEEDBACK
PLEASE WAIT ...
CLOSE
CLOSE

Manufacturer

Country

Registration Date 23 Aug 2022
Revision Date 23 Aug 2022
Share

Cimzia

(4)

Medicine Pharmaceuticals

Anti-inflammatory Drug

Drug Information

Generic
certolizumab pegol’ (CZP)
Drug Class
TNF alfa inhibitors
Therapeutic Class
anti-inflammatory
Dosage form
Solution
Route of Administration
SUBCUTANEOUS

Nanomaterials

Manufacturer Asserted

Polymeric Nanoparticle

Nanoparticle /Nanopowder

Benefit

Cimzia with the generic name ‘certolizumab pegol’ (CZP) received FDA approval in 2008, and is a PEGylated blocker of tumor necrosis factor alpha (TNF-α). Cimzia is a PEGylated Fab ’ fragment (part of a humanized IgG antibody without the Fc region) that specifically recognizes and binds to TNF-α, thus neutralizing its activity. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB Cimzia is used for treatment of patients with rheumatoid arthritis. Crohn’s disease, psoriatic arthritis and ankylosing spondylitis. These diseases all are somehow related to autoimmunity; an unhealthy immune response of the patient against his/her own healthy cells. Crohn’s disease is not an autoimmune disease since it seems that the content of the gut lumen triggers the response and not self-antigens. TNF-α is a pluripotent pro-inflammatory cytokine and could be one of the main cytokines responsible for the autoimmune attack.